Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

May 08, 2007

A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.

"Several clinical trials have confirmed the role of hormone therapy in recurrent ovarian cancer treatment, especially in patients with low-grade tumors," says review author Dr. Siqing Fu, an assistant professor of oncology at the University of Texas at Houston. "However, more research is needed to determine whether combining molecular-targeted therapy with hormonal therapy would be a more effective option."

Ovarian cancer is the deadliest of gynecological cancers; approximately 70 percent of patients are diagnosed in the later stages, when the 5-year survival rate drops below 25 percent. Traditional chemotherapy has proven to be generally ineffective against recurrent ovarian cancer, which has led researchers to investigate novel treatments.

"While a cure is unlikely, the goals of treatment are to control tumor-related symptoms and to improve or maintain quality of life," says Dr. Fu. "After surveying the latest research, combined molecular-targeted and hormonal therapy offers the greatest promise in achieving these goals and therefore deserves further investigation."

Source: Blackwell Publishing Ltd.

Explore further: Six percent of colorectal cancer found to be interval tumors

add to favorites email to friend print save as pdf

Related Stories

Menopausal hormone therapy may increase risk of ovarian cancer

Nov 09, 2010

Women planning on taking hormone therapy for the treatment of menopausal symptoms should be aware of a possible increased risk for ovarian cancer, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention ...

Recommended for you

Physicians target the genes of lung, colon cancers

9 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

Ebola virus in Africa outbreak is a new strain

The Ebola virus that has killed scores of people in Guinea this year is a new strain—evidence that the disease did not spread there from outbreaks in some other African nations, scientists report.

Freight train industry to miss safety deadline

The U.S. freight railroad industry says only one-fifth of its track will be equipped with mandatory safety technology to prevent most collisions and derailments by the deadline set by Congress.